Table 2.
Phase 3 patient demographics at baseline (full analysis set)
| Placebo (n=510) | RTB101 (n=511) | Overall (n=1021) | ||
|---|---|---|---|---|
| Age, years | ||||
| Mean (SD) | 73·1 (5·8) | 72·6 (5·8) | 72·8 (5·8) | |
| Median (range) | 72 (65–91) | 72·0 (65–93) | 72·0 (65–93) | |
| ≥85 | 24 (5%) | 23 (5%) | 47 (4·6%) | |
| ≥65–<85 | 486 (95%) | 488 (95%) | 974 (95·4%) | |
| Sex | ||||
| Male | 224 (44%) | 219 (43%) | 443 (43·4%) | |
| Female | 286 (56%) | 292 (57%) | 578 (56·6%) | |
| Ethnicity | ||||
| Hispanic or Latino | 7 (1%) | 1 (<1%) | 8 (0·8%) | |
| Non-Hispanic or Latino | 503 (99%) | 510 (>99%) | 1013 (99·2%) | |
| American Indian or Alaska Native | 0 | 0 | 0 | |
| Asian | 4 (<1%) | 9 (2%) | 13 (1·3%) | |
| Black or African American | 0 | 0 | 0 | |
| Native Hawaiian or other Pacific Islander | 8 (2%) | 11 (2%) | 19 (1·9%) | |
| White | 498 (98%) | 490 (96%) | 988 (96·8%) | |
| Other | 0 | 1 (<1%) | 1 (0·1%) | |
| Mean height, cm | 166·7 (9·9) | 167·4 (9·5) | 167·0 (9·7) | |
| Mean weight, kg | 80·1 (15·7) | 81·8 (17·0) | 81·0 (16·4) | |
| BMI, kg/m2 | 28·8 (5·1) | 29·2 (5·5) | 29·0 (5·3) | |
| Received current season influenza vaccination | ||||
| Yes | 407 (80%) | 415 (81%) | 822 (80·5%) | |
| No | 103 (20%) | 96 (19%) | 199 (19·5) | |
Data are n (%) or mean (SD), unless otherwise specified. Baseline weight and height were defined as the last measurement recorded before the first dose of study medication. BMI=body-mass index. * Age = (date of screening visit–date of birth + 1)/365·25, truncated to complete years.